Skip to main content
. 2013 Jun 20;22(21):4357–4367. doi: 10.1093/hmg/ddt285

Figure 3.

Figure 3.

Transcriptional activity of MITF mutations associated with WS2A, TS and melanoma. (A) Transcription activation ability of WS2A and TS mutant proteins from the TYR, TYRP1, DCT and 4M-box promoters. The data are shown as fold activation of MITF mutants over wild-type MITF. Error bars indicate the standard error of mean. (B) Transcription activation ability of WS2A and TS mutations from the MET promoter. The I212M and E213D mutations show hyperactivation from the MET promoter. The data are shown as fold activation of MITF mutants over wild-type MITF. Error bars indicate the standard error of mean. (C) Transcription activation ability of the melanoma mutations from the TYR, TYRP1, DCT, 4M-box and MET promoters. All cotransfection assays were repeated twice in six replicates and fold induction calculated over MITF wild type.